Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-spasticity agents for multiple sclerosis.

D T Shakespeare1, M Boggild, C Young

  • 1Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley - Liverpool, UK, L9 7LJ.

The Cochrane Database of Systematic Reviews
|October 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing lepton flavour violation via neutrinoless [Formula: see text] decays with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

A new method to distinguish hadronically decaying boosted <i>Z</i> bosons from <i>W</i> bosons using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for supersymmetry at [Formula: see text] TeV in final states with jets and two same-sign leptons or three leptons with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the differential cross-sections of prompt and non-prompt production of [Formula: see text] and [Formula: see text] in <i>pp</i> collisions at [Formula: see text] and 8 TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the transverse momentum and [Formula: see text] distributions of Drell-Yan lepton pairs in proton-proton collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Muon reconstruction performance of the ATLAS detector in proton-proton collision data at [Formula: see text]=13 TeV.

The European physical journal. C, Particles and fields·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Evidence for anti-spasticity agents in multiple sclerosis (MS) is limited. Current research shows poor documentation of efficacy and tolerability, preventing prescribing recommendations for MS spasticity management.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Spasticity is a prevalent and debilitating symptom in multiple sclerosis (MS) patients.
  • It leads to pain, spasms, functional loss, and challenges in patient care.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of anti-spasticity medications in MS patients.
  • To compare the effectiveness of different anti-spasticity agents.

Main Methods:

  • Systematic review of double-blind, randomized controlled trials (RCTs) of at least seven days duration.
  • Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to June 2003.
  • Data extraction by two independent reviewers; meta-analysis was not feasible due to study limitations.

Main Results:

Related Experiment Videos

  • Twenty-six placebo-controlled and thirteen comparative studies were included.
  • Few studies demonstrated statistically significant differences in spasticity reduction using the Ashworth scale.
  • Functional assessments were inconclusive, and other outcomes used unvalidated measures.

Conclusions:

  • The efficacy and tolerability of anti-spasticity agents for MS are poorly documented.
  • Current evidence does not support prescribing recommendations.
  • Further research is needed to understand the rationale for treating upper motor neuron syndrome and develop validated spasticity measures.